20-Year Study Shows Lifestyle Changes Outperform Medication in Preventing Multiple Chronic Diseases
A landmark 21-year follow-up study reveals that intensive lifestyle interventions in midlife reduce the long-term risk of developing multiple chronic conditions by 21%, a benefit not seen with the diabetes drug metformin.
By Factlen Editorial Team
- Public Health Advocates
- Emphasize the cost-effectiveness and broad societal benefits of funding lifestyle intervention programs.
- Clinical Researchers
- Focus on the data showing the limitations of glucose-lowering drugs in preventing broader systemic aging diseases.
- Medical Practitioners
- Highlight the practical challenges of sustaining behavioral changes in patients over decades compared to medication adherence.
What's not represented
- · Patients who face socioeconomic barriers to accessing safe exercise spaces and healthy foods.
- · Health insurance executives evaluating the cost-coverage of long-term behavioral counseling.
Why this matters
For the 115 million American adults with prediabetes, the choice between taking medication and changing daily habits is a major crossroad. This data proves that the hard work of diet and exercise pays off decades later by preventing a cascade of costly, debilitating chronic illnesses that medication alone cannot stop.
Key points
- A 21-year study tracked adults with prediabetes to compare lifestyle changes against the drug metformin.
- Intensive lifestyle interventions reduced the risk of developing multiple chronic conditions by 21%.
- Metformin effectively delayed diabetes but did not prevent the broader accumulation of other chronic diseases.
- The protective benefits of exercise and diet remained even for patients who eventually developed diabetes.
For the 115 million Americans currently living with prediabetes, the medical system often presents a stark choice: begin taking a daily medication to control blood sugar, or commit to the difficult work of overhauling diet and exercise habits. Until now, the long-term systemic differences between those two paths were not fully quantified.[1]
A landmark 21-year follow-up study published in the Journal of the American Medical Association (JAMA) has provided a definitive answer, offering a powerful endorsement for the long-term benefits of behavioral change.[3]
The Diabetes Prevention Program Outcomes Study (DPPOS) tracked participants for over two decades, revealing that intensive lifestyle interventions in midlife reduced the risk of developing multiple chronic conditions by 21% compared to a placebo group.[2][3]
Crucially, the study found that metformin—a widely prescribed and highly effective diabetes medication—offered no such broad protection against the accumulation of other chronic diseases.[2][5]

The original intervention required participants to achieve 150 minutes of moderate physical activity per week and lose at least 7% of their body weight through sustained dietary changes.[3][4]
Over the next two decades, those who adopted and maintained these habits experienced significantly lower rates of disease combinations involving stroke, chronic kidney disease, heart failure, and chronic obstructive pulmonary disease (COPD).[1][3]
The protective effect was most pronounced in preventing the costliest and most debilitating disease combinations, where the lifestyle group saw a remarkable 43% lower risk.[5]
Metformin effectively lowers blood sugar and delays the onset of diabetes, but the data shows its systemic benefits largely stop there.[2][5]
Metformin effectively lowers blood sugar and delays the onset of diabetes, but the data shows its systemic benefits largely stop there.
Researchers noted that while metformin reduced diabetes risk by 31% in the initial trial phase, it did not differ from a placebo in preventing the broader pileup of chronic illnesses over the 21-year span.[4][5]

This suggests that the mechanism of lifestyle intervention goes far beyond simple glycemic control, likely improving systemic inflammation, cardiovascular resilience, and metabolic health in ways a single targeted molecule cannot replicate.[2][6]
One of the most striking findings was that the lifestyle advantage remained statistically significant even when diabetes was excluded from the definition of multimorbidity.[3][5]
This means that even if a patient eventually develops diabetes, the years of healthy eating and exercise still protect their heart, brain, and lungs from other forms of age-related decline.[5][6]
The study is not without caveats. Because the multimorbidity outcome was tracked via Medicare claims during an observational follow-up period rather than the trial's strictly randomized initial phase, the findings represent a durable association rather than absolute proof of cause.[5]
Furthermore, lifestyle changes are not a permanent shield against diabetes. Over the 21-year follow-up, 60% of the participants in the lifestyle group still eventually developed type 2 diabetes.[5]

However, delaying the onset of the disease by several years—while simultaneously protecting against other life-altering conditions—represents a massive victory for individual longevity and quality of life.[4][6]
"Preventing diabetes is critically important, but preventing the accumulation of multiple chronic diseases as people age may have even broader implications for quality of life, independence, and healthcare costs," noted lead author Dr. Marcel Salive of the National Institute on Aging.[3]
How we got here
1996-1999
The Diabetes Prevention Program (DPP) enrolls over 3,000 adults with prediabetes to test lifestyle changes versus metformin.
2001
The initial trial phase ends early because lifestyle interventions proved overwhelmingly effective, reducing diabetes risk by 58%.
2002-Present
The Diabetes Prevention Program Outcomes Study (DPPOS) begins tracking the long-term health of the original participants.
June 2026
A 21-year follow-up analysis published in JAMA reveals that lifestyle interventions, but not metformin, significantly reduced the accumulation of multiple chronic diseases.
Viewpoints in depth
Public Health Advocates
Emphasize the cost-effectiveness and broad societal benefits of funding lifestyle intervention programs.
Public health officials and policy advocates view these findings as a mandate to restructure healthcare funding. They argue that the U.S. medical system heavily subsidizes pharmaceutical interventions like metformin while offering minimal coverage for behavioral counseling, gym memberships, or nutritional support. By proving that lifestyle changes reduce the costliest disease combinations by 43%, this camp argues that investing in community health programs is not just a medical imperative, but an economic one.
Clinical Researchers
Focus on the data showing the limitations of glucose-lowering drugs in preventing broader systemic aging diseases.
For researchers studying longevity and multimorbidity, the key takeaway is the stark contrast between the drug and the behavior. Metformin is highly effective at its primary job—lowering blood sugar—but this study dismantles the hope that glycemic control alone is the key to healthy aging. Researchers in this camp emphasize that moving the body and altering diet triggers systemic anti-inflammatory and cardiovascular benefits that a single targeted molecule cannot replicate.
Medical Practitioners
Highlight the practical challenges of sustaining behavioral changes in patients over decades compared to medication adherence.
While doctors universally applaud the benefits of diet and exercise, frontline medical practitioners point out the immense difficulty of replicating clinical trial results in the real world. The participants in the Diabetes Prevention Program received intensive, ongoing support to lose 7% of their body weight and maintain 150 minutes of weekly exercise. Practitioners note that without that scaffolding, many patients struggle to maintain lifestyle changes over 20 years, making medications like metformin a necessary, pragmatic fallback.
What we don't know
- Whether newer classes of weight-loss and diabetes drugs (like GLP-1 agonists) might offer the systemic multimorbidity protection that metformin lacked.
- How the results might differ for individuals who start lifestyle interventions later in life, as the study participants began in midlife.
- The exact biological mechanisms by which lifestyle changes prevent non-metabolic diseases like arthritis or COPD over such a long timeframe.
Key terms
- Prediabetes
- A condition where blood sugar levels are higher than normal but not yet high enough to be diagnosed as type 2 diabetes.
- Multimorbidity
- The co-occurrence of two or more chronic health conditions in the same person, such as diabetes, heart disease, and arthritis.
- Metformin
- A widely prescribed oral medication used to treat type 2 diabetes by lowering blood sugar levels and improving insulin sensitivity.
- Observational Follow-up
- A research phase where scientists track participants' health outcomes over time without actively controlling or randomizing their treatments.
Frequently asked
Did the lifestyle changes completely prevent diabetes?
No. Over the 21-year period, 60% of the participants in the lifestyle group still eventually developed type 2 diabetes, but the onset was significantly delayed.
What exactly was the lifestyle intervention?
Participants aimed to achieve 150 minutes of moderate physical activity per week, reduce dietary fat, and lose at least 7% of their body weight.
Does this mean patients should stop taking metformin?
No. Metformin remains highly effective at controlling blood sugar and delaying diabetes. However, the study suggests it should be paired with lifestyle changes to prevent other chronic diseases.
Sources
[1]NPRPublic Health Advocates
Winning strategy to prevent diabetes and related chronic diseases
Read on NPR →[2]MedPage TodayClinical Researchers
Lifestyle Change, Not Metformin, Linked to Less Chronic Disease
Read on MedPage Today →[3]JAMAClinical Researchers
Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults with Prediabetes
Read on JAMA →[4]National Institutes of HealthPublic Health Advocates
Long-term follow-up of the Diabetes Prevention Program shows sustained reductions in diabetes incidence
Read on National Institutes of Health →[5]EpocratesMedical Practitioners
Lifestyle change, not metformin, linked to less chronic disease
Read on Epocrates →[6]Factlen Editorial TeamMedical Practitioners
Synthesis by Factlen editorial team
Read on Factlen Editorial Team →
Every angle. Every day.
Get health stories with full source coverage and perspective breakdowns delivered to your inbox.








